Current status of immunotherapy for advanced gastric cancer | Zendy

Akihito Kawazoe | Zendy; Kohei Shitara | Zendy; Narikazu Boku | Zendy; Takaki Yoshikawa | Zendy; Masanori Terashima | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current status of immunotherapy for advanced gastric cancer

Author(s) -

Akihito Kawazoe,

Kohei Shitara,

Narikazu Boku,

Takaki Yoshikawa,

Masanori Terashima

Publication year - 2020

Publication title -

japanese journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.768

H-Index - 85

eISSN - 1465-3621

pISSN - 0368-2811

DOI - 10.1093/jjco/hyaa202

Subject(s) - pembrolizumab , medicine , nivolumab , pd l1 , immunotherapy , atezolizumab , cancer , blockade , oncology , microsatellite instability , programmed cell death 1 , immune checkpoint , monoclonal antibody , ipilimumab , antibody , immunology , receptor , allele , biochemistry , chemistry , microsatellite , gene

Recently, immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies have improved the overall survival of various types of cancers including advanced gastric cancer (AGC). Until now, two ant-PD-1 inhibitors were approved for AGC in Japan: nivolumab as third- or later-line treatment for AGC and pembrolizumab for previously treated patients with microsatellite instability-high tumours. However, a limited number of patients achieved clinical benefit, highlighting the importance of the better selection of patients or additional treatment to overcome resistance to PD-1/PD-L1 blockade. This review focused on pivotal clinical trials, biomarkers and novel combination therapy of immune checkpoint inhibitors forAGC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research